Annex 1: EU GMP Guidelines with Specific Requirements for the Manufacture of Sterile Medicinal Products
Last updated: 15. April 2026
As Annex 1 to the EU GMP Guide ("Manufacture of Sterile Medicinal Products"), Annex 1 specifies the requirements for the manufacture of sterile medicinal products. It sets out detailed regulatory expectations, protection goals, control principles, and detection methods. A central aspect is Container Closure Integrity (CCI) and the associated requirement for 100% integrity testing. The specifications are aimed at manufacturers, equipment suppliers, and service providers involved in aseptic processes, combining structural, technical, and organizational requirements into a consistent quality framework.
Scope and Fundamental Principles
The guideline applies to the manufacture of sterile medicinal products – both aseptically filled and terminally sterilized products. It covers fully automated production lines as well as processes with partial manual interventions. Furthermore, central basic principles can be transferred to other sterile applications. They require every process to be analyzed along potential contamination paths and for technical and organizational measures to be aligned in such a way that risks are systematically contained. Special attention is paid to the interaction between spatial design, air handling systems, and material logistics, as a multitude of transmission possibilities arise here. In addition, the guideline requires a closely monitored control environment in which cleanroom classes, cleaning concepts, and process parameters are clearly defined, monitored, and documented. The principles of seamless documentation and continuous improvement form the methodical framework that ensures manufacturing processes are not only qualified once but remain permanently controllable.
Limits for Microbiological Contamination
| Cleanroom Class | Air Sample (CFU/m³) | Impact Plates (CFU/4h) | Contact Plates (CFU/plate) |
| Grade A | <1 | <1 | <1 |
| Grade B | 10 | 5 | 5 |
| Grade C | 100 | 50 | 25 |
| Grade D | 200 | 100 | 50 |
The Central Pillar of Annex 1 - Contamination Control Strategy (CCS)
The Contamination Control Strategy (CCS) is at the heart of the regulatory framework and requires holistic prevention planning. In the glossary of Annex 1, the CCS is defined as a planned set of controls for microorganisms, endotoxins/pyrogens, and particles, derived from current product and process understanding, intended to ensure process performance and product quality. First, every process chain must be systematically analyzed to identify critical control points. This is followed by packages of measures that combine physical barriers, technical solutions, and procedural rules. Essential components of a CCS are:
- closed production zones and barrier systems
- standardized hygiene routines and clothing regulations
- validated cleaning and disinfection procedures
Additionally, the directive prescribes monitoring mechanisms that record particulate and microbiological data and enable trend analyses.
Process Design and Technical Requirements
In process design, the minimization of direct interventions plays a central role. The specifications favor closed systems, automatic controls, and technologies in which contact risks are reduced. Engineering measures concern, for example, airflow concepts, pressure zones, filter standards, and the physical separation of material and personnel flow. Furthermore, the regulations require traceable validation of technical equipment; this includes suitability tests, routine functional checks, and documentation proving reliable operation. For machine manufacturers, this results in requirements for design, cleanability, and accessibility for inspections.
Validation, Simulation, and Acceptance Criteria
The guideline requires robust evidence that aseptic processes can continuously deliver sterile products. Validations are based on comprehensive tests covering both individual processes and the overall system. Aseptic process simulations (e.g., media fill tests) are considered a central tool for identifying potential weaknesses. Additionally, the qualification of facility rooms, air handling systems, and control instruments is required. The release of production sequences must be tied to clearly defined criteria, including microbiological and particulate indicators. Through recurring tests and trend analyses, process control remains verifiable.
Personnel Rules and Training
Human behavior remains a significant source of contamination, which is why the directive formulates strict requirements for personnel qualification and behavior. For example, personnel may only be deployed in aseptic areas after specific training and qualification. Clothing regulations, rules of conduct in cleanrooms, and regular competency assessments are part of the organizational protection system. Furthermore, the guideline prescribes a clear assignment of responsibilities; thus, responsibilities for operations, quality assurance, and technical maintenance must be clearly regulated.
Impact and Technology Trends
The specifications lead to concrete changes in production planning, investment decisions, and supply chain coordination. Manufacturers are required to maintain CCS documentation, set up validation programs, and operate monitoring concepts. Suppliers, such as producers of primary packaging materials or cleaning chemicals, must be able to evaluate their products within the risk context of aseptic manufacturing. Overall, the regulatory framework brings about a stronger integration of technical, procedural, and organizational solutions along the entire value chain.
Innovation and Technology Trends in Implementation
With a view to practice, the regulation promotes technologies that reduce direct interaction and improve monitoring. Barrier systems, isolators, and automated filling platforms are gaining importance as they enable a stable separation of product and operators. In this context, BFS technology serves not only as an automated filling platform but as a particularly advanced aseptic filling technique that has addressed the current regulatory trend (closed systems, barriers) for decades. At the same time, the increasing use of digital technologies leads to new forms of monitoring and analysis: networked sensors, continuous data logging, and automated trend evaluations allow for faster action in the event of deviations.
Checkpoints for Practical Implementation
For practical implementation, a phased approach is recommended: First, a gap analysis should be performed to identify existing gaps compared to the specifications. Subsequently, priorities are set, measures are planned, and responsibilities are defined. Common packages of measures include adjustments to building and ventilation technology, the introduction of closed process lines, the updating of SOPs, and intensive employee training. Finally, validation, monitoring, and an audit cycle follow to ensure conformity.
Conclusion: Importance for Quality and Product Safety
The existing guideline formulates a stringent, practice-oriented framework for the manufacture of sterile products. By linking risk management, technology, and organization, it creates a basis on which processes become predictable, controllable, and auditable. In the long term, this orientation promotes more reliable processes that highly satisfy the requirements of authorities, customers, and end users.